Telomir Pharmaceuticals Advances Telomere-Targeting Drug, Seeks Strategic Partnerships

Telomir Pharmaceuticals is advancing its lead candidate Telomir-1, a small molecule designed to address core aging mechanisms by elongating telomeres. The company plans to submit an Investigational New Drug (IND) application to the FDA by the end of the year, with anticipated first-in-human dosing targeted for the first half of 2026.

The drug demonstrates potential therapeutic applications across multiple medical conditions, including rare diseases like Progeria, Werner's syndrome, and Wilson's disease, as well as more common health challenges such as Type 2 diabetes, aggressive prostate cancer, and macular degeneration.

At the upcoming BIO International Convention in Boston, Telomir will utilize BIO One-on-One Partnering to explore potential licensing, merger and acquisition, and strategic collaboration opportunities. The company is actively seeking FDA guidance on novel clinical endpoints to support accelerated development pathways.

Telomir's approach focuses on telomere science, targeting the protective end caps of chromosomes that naturally shorten with age. By developing a potential oral medication that can lengthen these DNA protective caps, the company aims to potentially slow or reverse aspects of the aging process and reduce associated degenerative disease risks.

The pharmaceutical industry and medical research community will likely watch Telomir's progress closely, as the drug represents a potentially significant advancement in longevity science with broad implications for human and animal health.